Testing gut bacteria and amino acids to clear hepatitis B surface marker
Part of Digestive system, Infections clinical trials.
This study tests whether a combination of a harmless gut bacterium (Bacteroides fragilis) and branched-chain amino acids (BCAAs, which are building blocks of protein) can help your body clear the hepatitis B surface antigen (HBsAg) from your blood. This may mean moving closer to a functional cure for chronic hepatitis B.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic hepatitis B (a long-lasting liver infection).
- You do not have any active cancer or history of cancer.
- You do not have other liver diseases (like fatty liver, cirrhosis from other causes, etc.).
- You are not pregnant (if female).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether extra treatment with peginterferon (a drug that boosts the immune system) can help lower the amount of hidden hepatitis B virus in the liver after you've already reached clinical cure. You'll have two liver biopsies to measure this, and the findings may help prevent the virus from coming back.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This study tests a combination of two medicines for chronic hepatitis B: pegylated interferon and a nucleoside analogue. The goal is to see if this combo helps clear the hepatitis B surface antigen and improves the chance of a functional cure.
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
This trial tests a new combination of medicines to help your body control the hepatitis B virus without needing lifelong treatment. It aims for a 'functional cure,' which means the virus stays inactive and your liver stays healthy.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.